Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
Recently, the U.S. Food and Drug Administration (FDA) issued a Drug Safety Communication that warns of an increased risk of diabetic ketoacidosis (DKA) with uncharacteristically mild to moderate glucose elevations (euglycemic DKA [euDKA]) associated with the use of all the approved sodium-glucose cotransporter 2 (SGLT2) inhibitors (1).This Communication was based on 20 clinical cases requiring hospitalization captured between March 2013 and June 2014 in the FDA Adverse Event Reporting System database.The scarce clinical data provided suggested that most of the DKA cases were reported in patients with type 2 diabetes (T2D), for whom this class of agents is indicated; most likely, however, they were insulintreated patients, some with type 1 diabetes (T1D).The FDA also identified potential triggering factors such as intercurrent illness, reduced food and fluid intake, reduced insulin doses, and history of alcohol intake.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with either T1DM or T2DM taking insulin are at particular risk, with the greatest risk for ketoacidosis in T1DM.”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [90]
In the citing paper
“Euglycemic ketoacidosis with minimal to no elevation in blood glucose levels may occur in patients taking SGLT2 inhibitors due to increased fatty acid oxidation and glucagon release along with decreased insulin secretion (89,90).”
From SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation (2021) · cites this paper as [90]
Citations
Cites
Nathan, D. M., & for the DCCT/EDIC Research Group (2014) · Diabetes Care · doi:10.2337/dc13-2112 · Cited by 1,832
Miller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134 · cited 4×
“Thus, in SGLT2-treated T2D patients (17), the lower insulin-to-glucagon ratio stimulated lipolysis (circulating FFAs were ;40% higher during the meal) and enhanced lipid oxidation (by 20% on av-”
BackgroundInfluentialSelf-citationPeters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0843 · Cited by 849
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795 · cited 1×
“of the euglycemic insulin clamp, as a result of attenuated glucotoxicity (21).”
BackgroundInternational Textbook of Diabetes Mellitus
(2004) · Wiley eBooks · doi:10.1002/0470862092 · Cited by 725
Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3828 · Cited by 670
Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program
Erondu, N., Desai, M., Ways, K., & Meininger, G. (2015) · Diabetes Care · doi:10.2337/dc15-1251 · Cited by 324
Euglycaemic Diabetic Ketoacidosis
Munro, J. F., Campbell, I. W., McCuish, A. C., & Duncan, L. J. P. (1973) · BMJ · doi:10.1136/bmj.2.5866.578 · Cited by 323
Insulin within islets is a physiologic glucagon release inhibitor
Maruyama, H., Hisatomi, A., Orci, L., Grodsky, G. M., & Unger, R. H. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111658 · Cited by 303 · cited 1×
“In contrast, plasma glucagon concentrations increased significantly, partly because of a diminished paracrine inhibition by insulin (18) and possibly also because of decreased SGLT2-mediated glucose transport intoa-cells (19).”
Background
Cited by
Items 401–500 of 685
Nakhleh, A., Othman, A., Masri, A., Zloczower, M., Zolotov, S., & Shehadeh, N. (2023) · Biomedicines · doi:10.3390/biomedicines11102689 · Cited by 6
“Prolonged exposure to elevated glucose concentrations can lead to pancreatic beta cell dysfunction which increases the risk for DKA [14].”
BackgroundZhou, Z., & Yao, X. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33306 · Cited by 7
“On the other hand, dapagliflozin can increase urinary glucose excretion, and blood glucose levels will approach normal when excretion is greater than endogenous glucose production [20].”
BackgroundKetoacidosis related to sodium glucose cotransporter 2 inhibitors after emergency coronary surgery
Horikoshi, R., Kitamura, T., & Miyaji, K. (2019) · Interactive Cardiovascular and Thoracic Surgery · doi:10.1093/icvts/ivz091 · Cited by 5
Immediate Euglycemic Diabetic Ketoacidosis After Gastric Bypass in a Patient with Type II Diabetes
Lo, Y.-T., Chen, K.-H., & Chang, P. (2021) · Obesity Surgery · doi:10.1007/s11695-021-05263-7 · Cited by 5
Acevedo-Mendez, B. A., Ye, Y., Hajizadeh, N., & Myers, A. K. (2021) · Cureus · doi:10.7759/cureus.19828 · Cited by 5
“SGLT-2i causes profound glucosuria which decreases plasma glucose levels and leads to increased glucagon secretion [10].”
BackgroundInfluentialIesaka, H., Nomoto, H., & Atsumi, T. (2023) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2023.04.003 · Cited by 6
SGLT2 Inhibitors: Far Too Many Cautions and Alerts and Limited Efficacy
Kabadi, U. M. (2016) · Journal of Diabetes Metabolic Disorders & Control · doi:10.15406/jdmdc.2016.03.00077 · Cited by 6
“Thus, despite a detailed description of the pathophysiologic mechanism and the reporting of several subjects in post marketing surveillance, manufacturers of these drugs continue to refute the significance of occurrence of Ketoacidosis based on the retrospective analysis of pre marketing clinical trials [47,48].”
BackgroundJaberi, A., Seth, B., Steenkamp, D., Alexanian, S. M., & Borkan, S. C. (2016) · Clinical Diabetes · doi:10.2337/cd16-0001 · Cited by 5
“• Potential effects of SGLT2 inhibitors on pancreatic islet cell function make this agent class relatively contraindicated in patients with either type 1 diabetes or LADA.”
BackgroundInfluentialDiabetic ketoacidosis in a postoperative gastric bypass patient
Hoenes, C., Rashid, Q. N., & Pimentel, J. (2017) · Journal of Surgical Case Reports · doi:10.1093/jscr/rjx148 · Cited by 5
“DKA, therefore, presents with hyperglycemia, glycosuria and hyperketonemia [1].”
BackgroundInhibiteur de la DPP-4 ou des SGLT2 après échec de la metformine seule dans le diabète de type 2
Paquot, N., & Scheen, A. J. (2017) · JMIG · doi:10.53738/revmed.2017.13.571.1410 · Cited by 5
Schwere atypische Ketoazidose durch SGLT2-Inhibitor-Therapie: Zwei Fallberichte
Breuer, T. G. K., Kampmann, K., Wutzler, A., Steinfort, C., Uhl, W., Schmidt, W. E., & Meier, J. J. (2017) · Der Internist · doi:10.1007/s00108-017-0316-y · Cited by 5
Continuing Professional Development: Diabetes and associated diabetic emergencies
Higginson, R., Burrows, P., & Jones, B. (2019) · Journal of Paramedic Practice · doi:10.12968/jpar.2019.11.6.cpd1 · Cited by 5
Glucagon in type 1 diabetes patients receiving SGLT2 inhibitors: A Friend or Foe?
Fukui, T., Ohara, M., & Yamagishi, S. (2020) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3415 · Cited by 5
“SGLT2i increase plasma glucagon levels and simultaneously reduce blood glucose and insulin levels in type 2 diabetes.(10,12) Dapagliflozin have been shown to stimulate glucagon secretion from pancreatic alpha cells as well.”
BackgroundMasri, D. E., Jamil, Y., & Fares, J. E. (2021) · AACE Clinical Case Reports · doi:10.1016/j.aace.2021.07.002 · Cited by 6
Case of sodium–glucose cotransporter-2 inhibitor-associated euglycaemic diabetic ketoacidosis
Yeoh, H. L., Lee, M., Pan, W. J., & Ong, H. Y. (2021) · BMJ Case Reports · doi:10.1136/bcr-2020-235953 · Cited by 6
Cüre, E., & Cüre, M. C. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.01.006 · Cited by 5
Hoque, S., Longo, R. R., Teague, P., & Kim, E. S. (2025) · Perioperative Medicine · doi:10.1186/s13741-025-00548-2 · Cited by 6
“…in patients with diabetes, there have been increasingly reported cases of SGLT2i-mediated eKA in patients without diabetes given more widespread use of this medication class (Garg et al. 2025; Khadka et al. 2024; Peters et al. 2015; Rosenstock and Ferrannini 2015; Umapathysivam et al. 2023).”
Várkonyi, T. T., Kupai, K., Kang, H. L., Matusovits, D., Priksz, D., Várkonyi, Á., Lengyel, C., & Pósa, A. (2026) · Antioxidants · doi:10.3390/antiox15050553 · Cited by 4
“These changes are typically hemodynamic in origin, explained by a decrease in glomerular intravascular pressure, and in many cases stabilize or are reversible with continued therapy [42–44].”
Euglykäme Ketoazidose – ein Kolibri, der zur Taube werden könnte
Kampmeyer, D., & Sayk, F. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1332-3750 · Cited by 7
Scott, S. N., HAYES, C. A., Zeuger, T., Davies, A. P., Andrews, R. C., & Cocks, M. S. (2023) · Diabetes Spectrum · doi:10.2337/dsi22-0015 · Cited by 6
Hedary, A. S., Melder, L., & Pippin, M. (2024) · Cureus · doi:10.7759/cureus.75399 · Cited by 4
Repurposing dapagliflozin for Alzheimer's disease: a mechanistic exploration
Saeed, M. M. (2024) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-024-00751-w · Cited by 5
“In comparison with other hypoglycemic agents, SGLT2i showed more reduction in HbA 1c satisfied for 1 year [94].”
SGLT 2 inhibitors in Type 1 diabetes: is this the future?
Herring, R. A., & Russell-Jones, D. L. (2018) · Diabetic Medicine · doi:10.1111/dme.13791 · Cited by 4
Smyth, C. C., Collins, M., McCarthy, J., & Galvin, S. (2021) · Interactive Cardiovascular and Thoracic Surgery · doi:10.1093/icvts/ivab104 · Cited by 4
Dehydration-induced AVP stimulates glucagon release and ketogenesis
Hill, T. G., Briant, L. J. B., Kim, A., Wu, Y., Rorsman, P., Asterholm, I. W., & Benrick, A. (2025) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00505.2024 · Cited by 5
Morey‐Vargas, O. L., Gossmann, M., Ketz, J. M., & Abdelmalak, B. (2025) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.92a.24118 · Cited by 4
“31 Precipitating factors for diabetic ketoacidosis in patients taking SGLT-2 inhibitors include a low-carbohydrate diet, dehydration, severe acute illness, and surgery.”
Bebernitz, G. R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12430-8 · Cited by 4
Rôle du glucagon dans la physiopathologie et le traitement du diabète
Girard, J. R., & Gautier, J. (2016) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(16)30207-3 · Cited by 4
Tratamiento de la diabetes tipo 2
Rigalleau, V., Cherifi, B. G., Blanco, L., Alexandre, L., & Mohammedi, K. (2018) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(18)89306-0 · Cited by 4
Burgio, A., Alletto, M., Amico, S., Castiglione, U., Fulco, G., Groppuso, C., Gruttadauria, G., Salvaggio, S., Grande, A., & Vancheri, F. (2018) · Italian Journal of Medicine · doi:10.4081/itjm.2018.1061 · Cited by 4
Schwere Azidose: Differenzialdiagnostik und Therapie
Lehner, L. J., Oppert, M., & Kettritz, R. (2019) · Der Nephrologe · doi:10.1007/s11560-019-00374-w · Cited by 4
SGLT2-Hemmer als Ursache für die Entstehung einer Ketoazidose
Emmelheinz, M., Roden, M., & Müssig, K. (2019) · Diabetologie und Stoffwechsel · doi:10.1055/a-1011-8694 · Cited by 4
“Anaesthesia 2018; 73: 1008–1018 [14] Rosenstock J, Ferrannini E.”
O'Neill, R. S., Tyack, L. T., Freeman, M., & Hussein, H. S. (2020) · Case Reports in Endocrinology · doi:10.1155/2020/8882299 · Cited by 4
“-is -is is postulated to occur through decreasing fasting and postprandial glucose levels resulting in decreased insulin production and subsequently has been shown to promote hyperglucagonemia, along with the propagation of a negative fluid and sodium balance [4, 5].”
Euglycemic Diabetic Ketoacidosis in the Surgical Patient
McCabe, D. E., Strollo, B. P., & Fuhrman, G. M. (2020) · The American Surgeon · doi:10.1177/0003134820956352 · Cited by 4
Wibawa, K., Kuhuwael, F. V., Putra, C. R. J., Widiastuti, S. U., & Suciadi, L. P. (2021) · Clinical Diabetology · doi:10.5603/dk.a2021.0010 · Cited by 5
“3 mEq/L, intravenous insulin can be safely given along with intravenous dextrose 5% to avoid hypoglycaemia [3, 5].”
BackgroundMarked Hypertriglyceridemia in a Patient with type 2 Diabetes Receiving SGLT2 Inhibitors.
Senoo, M., Tone, A., Imai, Y., Watanabe, S., Kaneto, M., Shimomura, Y., Teshigawara, S., & Nakatou, T. (2021) · Institutional Repositories DataBase (IRDB) · doi:10.18926/amo/61441 · Cited by 5
Euglycemic Diabetic Ketoacidosis after a Single Dose of Empagliflozin in a Patient with Pancreatitis
Calçada, M. B., Fernandes, L. G. D. M., Costa, R. S., Montezinho, S., Duarte, F. M., Frutuoso, L., & Freitas, A. R. (2021) · Clinics and Practice · doi:10.3390/clinpract11020031 · Cited by 5
“3 and serum bicarbonate <18 mEq/L, ketosis, and serum glucose >200 mg/dL [6,7].”
BackgroundScarr, D., Lovblom, L. E., Ye, H., Liu, H., BAKHSH, A. M. K., Verhoeff, N. J., Wolever, T. M. S., Lawler, P. R., Sharma, K., Cherney, D. Z. I., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.111031 · Cited by 4
Diabetic Ketoacidosis and New Onset Diabetes Mellitus Precipitated by COVID-19 Infection
Alotair, H., Sheshah, E., Shirah, B. Z. A., & Jammah, A. A. (2020) · Juniper Online Journal of Case Studies · doi:10.19080/jojcs.2020.11.555815 · Cited by 4
Dapagliflozin combination therapy in type 2 diabetes mellitus
Yacoub, T. G. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2016.1111119 · Cited by 6
“(N > 18,000),[139] the incidence of DKA was reported to be”
BackgroundGLP-1 mimetics and diabetic ketoacidosis: possible interactions and clinical consequences
Forouzanmehr, B., Hemmati, M. A., Atkin, S. L., Jamialahmadi, T., Yaribeygi, H., & Sahebkar, A. (2025) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-024-03384-1 · Cited by 3
“Consequently, this exchanger indirectly aids in regulating blood pH and preventing ketoacidosis (Yaribeygi et al. 2022a; Rosenstock and Ferrannini 2015; Martinez et al. 2018).”
Optimising outcomes in feline diabetes: SGLT2 inhibitor use
Covey, E. B. (2025) · The Veterinary Nurse · doi:10.12968/vetn.2025.0034 · Cited by 3
Tirzepatide-induced ketoacidosis with hyperglycemia in a patient without diabetes
Shloush, M., Rodriguez, V., Guillen, V., & Baruqui, D. L. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2026-0028 · Cited by 5
“Euglycemic ketoacidosis involves high anion gap acidosis and elevated ketones without significant hyper-glycemia (7).”
Progress in the Presence of Failure: Updates in Chronic Systolic Heart Failure Management
Murphy, K. M., & Rosenthal, J. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0552-4 · Cited by 5
Euglycemic Diabetic Ketoacidosis in the Setting of Dulaglutide Use
Patel, N., Reddy, A. D., Romero, K. N., & Reddy, P. (2025) · Cureus · doi:10.7759/cureus.82143 · Cited by 3
“Common risk factors include dehydration, pregnancy, prolonged fasting, pancreatitis, abuse of cocaine, infections, bariatric surgery, liver cirrhosis, gastroparesis, insulin pump malfunction, and glycogen storage disorders [6].”
Managing diabetic ketoacidosis in special conditions: Difficulties and dilemmas
Ray, S., & Palui, R. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i9.109053 · Cited by 3
Empagliflozin-Associated Euglycemic Diabtetic Ketoacidosis
Soni, P., Kumar, V., Saradna, A., & Kupfer, Y. Y. (2018) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000752 · Cited by 3
Lunder, M., Janić, M., Šabović, M., & Janež, A. (2018) · Slovenian Medical Journal · doi:10.6016/zdravvestn.2705 · Cited by 3
Kumar, S., Talwalkar, P., Das, S., & Goswami, S. (2019) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_161_17 · Cited by 3
“1% for blinded DKA events in ≈ 7000 patients.[27-29]”
BackgroundMise au point sur le profil de tolérance de la classe des inhibiteurs de SGLT2
Gourdy, P. (2019) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(19)30063-x · Cited by 4
Evaluation of Dapagliflozin in the Treatment of Heart Failure
Sotirakos, S. (2020) · Future Cardiology · doi:10.2217/fca-2020-0138 · Cited by 3
Shamchuk, A. L., Doulla, M., & Jetha, M. M. (2021) · Canadian Medical Association Journal · doi:10.1503/cmaj.202627 · Cited by 3
Clinical Use of Insulin Glargine 300 U/mL in Adults with Type 2 Diabetes: Hypothetical Case Studies
Harris, S. B., Parente, E. B., & Karalliedde, J. J. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01247-7 · Cited by 3
“This is particularly important as an increased risk of diabetic ketoacidosis (DKA) has been reported in people prescribed both SGLT2 and insulin, with potential triggering factors including illness, reduced food or liquid intake, and a reduction in insulin doses [82].”
BackgroundNewer Glucose-Lowering Medications and Potential Role in Metabolic Management of PCOS
Anam, A. K., & Inzucchi, S. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-92589-5_26 · Cited by 3
Reddi, A. S. (2019) · Springer eBooks · doi:10.1007/978-3-030-28895-2_6 · Cited by 3
Alhaj, O., & Afandi, B. O. (2022) · Journal of Diabetes and Endocrine Practice · doi:10.1055/s-0042-1755440 · Cited by 3
Ess, M. S. E., & Elrishi, M. (2023) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000000479 · Cited by 3
In Search of Novel SGLT2 Inhibitors by High-throughput Virtual Screening
Debnath, A., Sharma, S., Mazumder, R., Mazumder, A., Singh, R. K., Kumar, A., Dua, A., Singhal, P., Kumar, A., & Singh, G. (2023) · Current Drug Discovery Technologies · doi:10.2174/0115701638267615231123160650 · Cited by 3
The Ketone Bridge Between the Heart and the Bladder: How Fast Should We Go?
Faria‐Costa, G., Oliveira, J., Vilas-Boas, I., Campelo, I., Silva, E. A., Brás‐Silva, C., Silva, S. M., Antunes‐Lopes, T., & Charrua, A. (2024) · International Neurourology Journal · doi:10.5213/inj.2346250.125 · Cited by 3
Yoshida, Y., Fujimoto, Y., Konishi, H., Sato, E., Iwata, H., Ouchi, S., Naito, R., Hayashi, H., Matsue, Y., & Minamino, T. (2025) · Internal Medicine · doi:10.2169/internalmedicine.4752-24 · Cited by 3
Fu, Y., Yang, A., & Yan, F. (2017) · Springer eBooks · doi:10.1007/978-3-319-69362-0_12 · Cited by 3
Novel approaches to the treatment of hyperglycaemia in type 2 diabetes mellitus
Galligan, A., & Greenaway, T. M. (2016) · Internal Medicine Journal · doi:10.1111/imj.13070 · Cited by 3
Diabetic ketoacidosis without hyperglycemia as a complication of SGLT2 inhibitors treatment
Trojanowska-Grigoriew, M., & Majkowska, L. (2016) · Clinical Diabetology · doi:10.5603/dk.2016.0011 · Cited by 3
“50% of daily carbohydrate intake, for both men and women [34].”
BackgroundJiménez, D. L., Huelgas, R. G., Romero, A. J. F., Chozas, J. M. L., de Isla, L. P., & Miramontes‐González, J. P. (2018) · Revista Clínica Española · doi:10.1016/j.rce.2018.09.021 · Cited by 3
Jiménez, D. L., Huelgas, R. G., Romero, A. J. F., Chozas, J. M. L., de Isla, L. P., & Miramontes‐González, J. P. (2019) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2019.01.001 · Cited by 3
Hyperglycemic Crises in Patients with COVID-19
Mikhail, N. E., & Wali, S. (2020) · Journal of Pathology and Infectious Diseases · doi:10.33309/2639-8893.030105 · Cited by 3
“DKA presenting with relatively low blood glucose levels (<250 mg/dl) may uncommonly occur as adverse effects of sodium-glucose cotransporters type 2 (SGLT-2) inhibitors approved for treatment of type 2 diabetes [21].”
BackgroundSteen, O., & Goldenberg, R. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.11.008 · Cited by 2
RetractedSoni, H. (2015) · MOJ Toxicology · doi:10.15406/mojt.2015.02.00021 · Cited by 2
Small, A. M., & Wiviott, S. D. (2024) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.24.06600-6 · Cited by 3
Kaur, J., Dogra, A., & Haymov, A. (2025) · Cureus · doi:10.7759/cureus.95681 · Cited by 2
“Because hyperglycemia is often absent or mild, recognition of this complication is frequently delayed, emphasizing the importance of clinician awareness [5,7,8].”
Bian, E., Zou, W.-W., Zhu, Q.-K., Zhuang, W.-Z., Chen, J.-M., Cen, J., & Gao, Q. (2026) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-026-04141-6 · Cited by 2
Hafer, C. (2016) · Intensivmedizin up2date · doi:10.1055/s-0041-110071 · Cited by 2
Aung, E. T., Koshy, R. M., & Jacob, K. (2019) · Practical Diabetes · doi:10.1002/pdi.2217 · Cited by 2
Histology of Cryopreserved Neonatal Rat Testes After Intratesticular Allotransplantation
Deng, B., Kireev, V. A., Melentyeva, K. V., Kovalenko, I., & Pakhomov, O. V. (2020) · Problems of Cryobiology and Cryomedicine · doi:10.15407/cryo30.01.034 · Cited by 2
What is the effect of COVID-19 on people with diabetes?
Morris, D. (2020) · Independent Nurse · doi:10.12968/indn.2020.5.12 · Cited by 3
Matos, S., de Carvalho, F. S., Duarte, A., Marqués, F. M. P., Miranda, M., Gomes, V., & Almeida, M. (2021) · Revista Portuguesa de Saúde Ocupacional · doi:10.31252/rpso.18.12.2021 · Cited by 3
Diabetic, Alcoholic, and Starvation Ketoacidosis
Reddi, A. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-25810-7_32 · Cited by 2
Euglycemic diabetic ketoacidosis following traumatic brain injury
Jang, S. W., & Lee, H. (2024) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2024.01.006 · Cited by 2
Use of Sodium-Glucose Cotransporter Inhibitors in Type 1 Diabetes: The Promise and the Perils
Peter, P. R., & Inzucchi, S. E. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.03.022 · Cited by 3
Korekawa, K., Mitsugashira, H., Yashima, Y., & Asakura, T. (2024) · Internal Medicine · doi:10.2169/internalmedicine.4327-24 · Cited by 2
Devkota, B., Maxwell, T., Schaedel, J. F., Wagener, B. M., Song, W., & Nooli, N. P. (2024) · Cureus · doi:10.7759/cureus.71931 · Cited by 3
“Increased lipolysis leads to heightened activity of carnitine palmitoyl transferase I (CPT I), facilitating beta-oxidation of fatty acids within mitochondria, and thereby inducing ketogenesis (Figure 1 ) [15,16].”
Chai, J.-T., Li, X., & Jiang, Z. (2025) · World Journal of Clinical Cases · doi:10.12998/wjcc.v13.i27.108550 · Cited by 2
“These hormonal changes accelerate β -oxidation of free fatty acids (FFAs), leading to excessive ketone body production, while reducing ketone utilization in other tissues[19].”
Martinka, E., Uličiansky, V., Mokáň, M., Tkáč, I., Galajda, P., Dókušová, S., & Schroner, Z. (2018) · Vnitřní lékařství · doi:10.36290/vnl.2018.059 · Cited by 2
“Za potenciálne spúšťacie mechanizmy sa považuje interkurentné ochorenie, dehydratácia, chirurgický zákrok, stres, znížený príjem potravy a tekutín, redukcia dávok inzulínu, nízka funkčná rezerva B-buniek, zvýšené nároky na inzulín, požitie alkoholu [52].”
Les acidocétoses diabétiques atypiques
Schlienger, J.-L., & Halimi, S. (2016) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(16)30118-3 · Cited by 4
Sodium Glucose Cotransporter-2 Inhibitors in Clinical Practice: Impact beyond Glycemic Control
Rao, N. K., & KUMAR, K. M. P. (2016) · Hypertension Journal · doi:10.5005/jp-journals-10043-0035 · Cited by 2
Kountz, D. S. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1313074 · Cited by 2
“The risk of euglycemic DKA may be associated with longstanding T2D with marked beta-cell insufficiency, or latent autoimmune diabetes in adults with rapid evolution to type 1 diabetes, or in other severe medical conditions.[45]”
BackgroundCanagliflozin-associated diabetic ketoacidosis with lower-than-anticipated glucose levels
Agarwal, M. (2017) · Indian Journal of Critical Care Medicine · doi:10.4103/ijccm.ijccm_328_17 · Cited by 2
Evaluating the Evidence behind the Novel Strategy of Early Combination from Vision to Implementation
Paldánius, P. M. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0179 · Cited by 2
“SGLT-2is have exciting data especially in later populations with concomitant CV disease [115], while reports of euglycaemic ketoacidosis and genitourinary tract infections warrant careful patient selection and better delineation of the populations who may be at risk [116,117].”
BackgroundManaging diabetes during the COVID-19 pandemic
Morris, D. (2020) · Practice Nursing · doi:10.12968/pnur.2020.31.11.450 · Cited by 2
Effect of sodium-glucose cotransporter-2 inhibitors on renal handling of electrolytes
Meena, P., Bhargava, V., Bhalla, A. K., Rana, D. S., & Mantri, A. K. (2021) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2020-139348 · Cited by 2
Ahmed, T., Karimi, H., Hegde, V., & Lodhi, S. H. (2021) · Cureus · doi:10.7759/cureus.19169 · Cited by 3
“Originally described in type 1 diabetes mellitus (DM), the pathophysiology involves low insulin to glucagon ratio in the presence of a restricted pool of plasma glucose [1].”
BackgroundKinoshita, M., Azuma, K., & Yanagawa, T. (2022) · Journal of Clinical and Translational Endocrinology Case Reports · doi:10.1016/j.jecr.2022.100124 · Cited by 2
Instituto de Salud del Estado de México. Calixtlahuaca, T., Sanchez, D. S. M., Larios, J. F. D. P., Instituto de Salud del Estado de México. Calixtlahuaca, T., Salas, J. M. G., Instituto de salud del Estado de México, C. E. D. A. P. A. L. S. S. J. D. L. H., Salazar, J. A. D., Jurisdicción IX Ameca; Centro de Salud. San Marcos, J., García, G. L., & Instituto de salud del Estado de México, C. E. D. A. P. A. L. S. S. J. D. L. H. (2023) · International Journal of Medical Science and Clinical Research Studies · doi:10.47191/ijmscrs/v3-i4-22 · Cited by 2
The Role of Dietary Interventions in the Management of Obesity
Ullah, A., Jamil, M., & Jamil, J. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.111529 · Cited by 3
Gao, Y., Zhong, M., Gan, L., Xiang, C., Li, L., & Yan, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1236946 · Cited by 2
“Notably, SGLT-2 inhibitors can causeDKA, characterized bymild insulin deficiency and insulin resistance (40), and the blood glucose level usually approachesnormalor slight elevation (<288mg/dL)when DKA occurs (41).”
BackgroundDiabetes in the Critically Ill Patient: DKA, HHS, and Beyond
Singh, B., Chlebek, S., & Krikorian, A. (2023) · Contemporary Endocrinology · doi:10.1007/978-3-031-44648-1_5 · Cited by 2
Rosenstock, J., & Ferrannini, E. (2016) · Diabetes Care · doi:10.2337/dci16-0005 · Cited by 2
“Cushard felt uneasy (1) with our commentary (2) stating that euglycemic diabetic ketoacidosis (euDKA) induced by sodium–glucose cotransporter 2 inhibitors (SGLT2i) was”
Self-citationCushard, W. G. (2016) · Diabetes Care · doi:10.2337/dc15-1948 · Cited by 2
“I felt uneasy about the assessment by Rosenstock and Ferrannini (1) that euglycemic diabetic ketoacidosis (euDKA) associated with sodium–glucose cotransporter 2 inhibitor (SGLT2i) therapy”
InfluentialThapa, S. S., Lal, A., Ömer, A., & Trivedi, N. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2019.04.021 · Cited by 2
Schernthaner-Reiter, M. H., & Schernthaner, G. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2016.1151783 · Cited by 1
Metadata
- Authors
- Rosenstock, J., & Ferrannini, E.
- Affiliations
- Medical City Dallas Hospital (US)
- Istituto di Fisiologia Clinica (IT)
- Corresponding author
- Rosenstock, Julio
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-08-10
- Volume
- 38
- Issue
- 9
- Pages
- 1638-1642
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1955935325
- Cited by
- 664
- References
- 21
- Citations by year
- 2026: 23 · 2025: 33 · 2024: 55 · 2023: 36 · 2022: 43 · 2021: 68 · 2020: 89 · 2019: 79 · 2018: 67 · 2017: 75 · 2016: 77 · 2015: 18
- FWCI
- 68.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- euglycemic diabetic ketoacidosis, SGLT2 inhibitors, drug safety, type 2 diabetes, type 1 diabetes, insulin-treated patients, adverse drug reactions, risk factors, alcohol consumption, intercurrent illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.